Here's Why Viatris (VTRS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
VTRS - Viatris Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$21.00
DETAILS
HIGH:
$22.00
LOW:
$20.00
MEDIAN:
$21.00
CONSENSUS:
$21.00
UPSIDE:
28.68%
Stock News
Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript
Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript
Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued
On August 06, 2026, Viatris Inc (VTRS) shares fell 7.6%, closing at $16.29. Over the past year, the stock has seen significant volatility, with a 52-week high o
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Harrow Inc. (NASDAQ:HROW) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ:VTRS).
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates
Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago.
Is Viatris Inc (VTRS) Worth the Investment After Q2 Earnings? EPS at $0.69, Revenue of $3,756.8 Million with GF Score of 58/100
Viatris Inc (VTRS) released its 8-K filing on August 6, 2026, detailing its financial results for the second quarter of 2026. The company, formed in 2020 from t
Viatris Reports Second-Quarter 2026 Financial Results
Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025 Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn LoTM Announces Sale of Global Rights to Tyrvaya® Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH, Aug. 6, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its second-quarter 2026 financial results. Executive Commentary "Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business," said Scott A.
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.
Viatris Announces Quarterly Dividend
PITTSBURGH, Aug. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 16, 2026, to shareholders of record as of the close of business on August 21, 2026.
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option Approval Marks an Important Milestone in Viatris' Efforts to Advance Women's Health PITTSBURGH, July 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen.
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
VTRS or DHR: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Should Value Investors Buy Viatris (VTRS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
Price Targets
Viatris price target raised to $22 from $17 at Barclays
$22.00
(was $16.50)
Glen Santangelo
·
Barclays
Viatris price target raised to $20 from $18 at Truist
$20.00
(was $16.95)
Truist Financial
Viatris upgraded to Buy from Neutral at UBS
$18.00
(was $14.58)
Ashwani Verma
·
UBS
Viatris price target raised to $12 from $9 at Piper Sandler
$12.00
(was $13.12)
Piper Sandler
Argus upgrades Viatris to Buy on expected buybacks, debt reduction
$15.00
(was $12.84)
Argus Research
Viatris price target raised to $16 from $15 at Truist
$16.00
(was $12.40)
Les Sulewski
·
Truist Financial
Viatris initiated with a Buy at Truist
$15.00
(was $9.93)
Truist Financial
Viatris reinstated with a Buy at Jefferies
$15.00
(was $11.77)
Glen Santangelo
·
Jefferies
Viatris (VTRS) PT Raised to $13 at Piper Sandler on latest Idorsia deals
$13.00
(was $11.83)
David Amsellem
·
Piper Sandler
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
$10.00
(was $9.84)
David Amsellem
·
Piper Sandler
Barclays Maintains Overweight on Viatris, Lowers Price Target to $15
$15.00
(was $12.16)
Barclays
UBS Upgrades Viatris (VTRS) to Neutral
$12.00
(was $10.83)
Ashwani Verma
·
UBS
Viatris initiated with a Sell at UBS
$9.00
(was $10.77)
Ashwani Verma
·
UBS